Search

Your search keyword '"Andersen, Mads Hald"' showing total 897 results

Search Constraints

Start Over You searched for: Author "Andersen, Mads Hald" Remove constraint Author: "Andersen, Mads Hald"
897 results on '"Andersen, Mads Hald"'

Search Results

105. Identification of heme oxygenase-1--specific regulatory [CD8.sup.+] T cells in cancer patients

108. Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms

109. Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study

112. Cancer immune therapy for Philadelphia chromosome-negative chronic myeloproliferative neoplasms

113. The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines

114. Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma:A Phase I First-in-Human Trial

115. MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas

116. Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade

117. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8 + and CD4 + T-cell-mediated antitumor immunity and enhanced anti-PD1 responses

118. Healthy donors harbor memory T cell responses to RAS neo-antigens

119. Staphylococcus aureus alpha-toxin inhibits CD8+ T cell-mediated killing of cancer cells in cutaneous T-cell lymphoma

120. Survivin

123. Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial

127. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+ and CD4+ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses

129. MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas

130. The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines

131. Staphylococcus aureus alpha-toxin inhibits CD8+ T cell-mediated killing of cancer cells in cutaneous T-cell lymphoma

132. Therapeutic Cancer Vaccines

135. Cytotoxic T Cells

138. Inflammation induced PD-L1-specific T cells

139. Expression and function of Kv1.3 channel in malignant T cells in Sézary syndrome

140. Staphylococcal alpha-toxin tilts the balance between malignant and non-malignant CD4+ T cells in cutaneous T-cell lymphoma

141. Cancerimmunterapi til behandling af hæmatologisk cancer

142. Terapeutisk cancervaccination mod hæmatologisk cancer

143. The targeting of tumor-associated macrophages by vaccination

144. Cancer immune therapy for lymphoid malignancies: recent advances

146. The T-win® technology:immune-modulating vaccines

147. Arginase-1-based vaccination against the tumor microenvironment:the identification of an optimal T-cell epitope

148. MERTK Acts as a costimulatory receptor on human cd8 t cells

149. Immunoprofiles of colorectal cancer from Lynch syndrome

150. Neo-antigen specific memory T-cell responses in healthy individuals

Catalog

Books, media, physical & digital resources